Ascentage Pharma Group Stock Net Income
| ASPHF Stock | USD 8.48 0.00 0.00% |
As of the 8th of February, Ascentage Pharma shows the mean deviation of 0.5103, and Risk Adjusted Performance of (0.03). Ascentage Pharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Ascentage Pharma risk adjusted performance, standard deviation, as well as the relationship between the Standard Deviation and maximum drawdown to decide if Ascentage Pharma is priced correctly, providing market reflects its regular price of 8.48 per share. Given that Ascentage Pharma has variance of 5.82, we suggest you to validate Ascentage Pharma Group's prevailing market performance to make sure the company can sustain itself at a future point.
Ascentage Pharma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Ascentage Pharma's valuation are provided below:Ascentage Pharma Group does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Ascentage |
Ascentage Pharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Ascentage Pharma's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Ascentage Pharma.
| 11/10/2025 |
| 02/08/2026 |
If you would invest 0.00 in Ascentage Pharma on November 10, 2025 and sell it all today you would earn a total of 0.00 from holding Ascentage Pharma Group or generate 0.0% return on investment in Ascentage Pharma over 90 days. Ascentage Pharma is related to or competes with Galenica, and Sugi Holdings. More
Ascentage Pharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Ascentage Pharma's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Ascentage Pharma Group upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.08) | |||
| Maximum Drawdown | 16.95 |
Ascentage Pharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Ascentage Pharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Ascentage Pharma's standard deviation. In reality, there are many statistical measures that can use Ascentage Pharma historical prices to predict the future Ascentage Pharma's volatility.| Risk Adjusted Performance | (0.03) | |||
| Jensen Alpha | (0.16) | |||
| Total Risk Alpha | (0.36) | |||
| Treynor Ratio | (0.27) |
Ascentage Pharma February 8, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.26) | |||
| Mean Deviation | 0.5103 | |||
| Coefficient Of Variation | (2,153) | |||
| Standard Deviation | 2.41 | |||
| Variance | 5.82 | |||
| Information Ratio | (0.08) | |||
| Jensen Alpha | (0.16) | |||
| Total Risk Alpha | (0.36) | |||
| Treynor Ratio | (0.27) | |||
| Maximum Drawdown | 16.95 | |||
| Skewness | (4.38) | |||
| Kurtosis | 41.36 |
Ascentage Pharma Backtested Returns
Ascentage Pharma secures Sharpe Ratio (or Efficiency) of -0.0472, which signifies that the company had a -0.0472 % return per unit of standard deviation over the last 3 months. Ascentage Pharma Group exposes sixteen different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Ascentage Pharma's risk adjusted performance of (0.03), and Mean Deviation of 0.5103 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.45, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Ascentage Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Ascentage Pharma is expected to be smaller as well. At this point, Ascentage Pharma has a negative expected return of -0.12%. Please make sure to confirm Ascentage Pharma's standard deviation, as well as the relationship between the maximum drawdown and day median price , to decide if Ascentage Pharma performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.00 |
No correlation between past and present
Ascentage Pharma Group has no correlation between past and present. Overlapping area represents the amount of predictability between Ascentage Pharma time series from 10th of November 2025 to 25th of December 2025 and 25th of December 2025 to 8th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Ascentage Pharma price movement. The serial correlation of 0.0 indicates that just 0.0% of current Ascentage Pharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | -0.29 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Ascentage Pharma Group reported net income of (782.42 Million). This is 329.26% lower than that of the Healthcare sector and significantly lower than that of the Biotechnology industry. The net income for all United States stocks is significantly higher than that of the company.
Ascentage Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ascentage Pharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Ascentage Pharma could also be used in its relative valuation, which is a method of valuing Ascentage Pharma by comparing valuation metrics of similar companies.Ascentage Pharma is currently under evaluation in net income category among its peers.
Ascentage Fundamentals
| Return On Equity | -0.7 | |||
| Return On Asset | -0.22 | |||
| Operating Margin | (8.63) % | |||
| Current Valuation | 844.8 M | |||
| Shares Outstanding | 287.77 M | |||
| Shares Owned By Insiders | 26.81 % | |||
| Shares Owned By Institutions | 11.60 % | |||
| Price To Book | 12.28 X | |||
| Price To Sales | 14.53 X | |||
| Revenue | 27.91 M | |||
| Gross Profit | 24.58 M | |||
| EBITDA | (802.15 M) | |||
| Net Income | (782.42 M) | |||
| Total Debt | 1.03 B | |||
| Book Value Per Share | 3.39 X | |||
| Cash Flow From Operations | (604.68 M) | |||
| Earnings Per Share | (0.46) X | |||
| Number Of Employees | 600 | |||
| Beta | 1.34 | |||
| Market Capitalization | 1.18 B | |||
| Total Asset | 2.94 B | |||
| Z Score | 0.6 | |||
| Net Asset | 2.94 B |
About Ascentage Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ascentage Pharma Group's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ascentage Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ascentage Pharma Group based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Additional Information and Resources on Investing in Ascentage Pink Sheet
When determining whether Ascentage Pharma is a strong investment it is important to analyze Ascentage Pharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ascentage Pharma's future performance. For an informed investment choice regarding Ascentage Pink Sheet, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Ascentage Pharma Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.